Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,184.69
+5.76 (+0.49%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
39
40
Next >
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
May 20, 2024
Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions.
Via
InvestorPlace
Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encourages Investors to Contact the Firm
May 19, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
May 17, 2024
Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world’s largest pre-college science, technology, engineering and math (STEM) competition.
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector
May 17, 2024
Via
Benzinga
Assessing Regeneron Pharmaceuticals: Insights From 16 Financial Analysts
May 03, 2024
Via
Benzinga
Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)
May 16, 2024
From
Kirby McInerney LLP
Via
Business Wire
These 2 No-Brainer Growth Stocks Are Breaking New Ground
May 16, 2024
The future keeps getting brighter for these companies.
Via
The Motley Fool
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 10 Years
May 14, 2024
Via
Benzinga
Week Of May 13, 2024: What's In Store For The Markets
May 13, 2024
Timeless Wisdom and timely ideas including general market commentary along with stocks to watch.
Via
Talk Markets
Healthcare And Biotech Investing 101: What You Need To Know.
May 13, 2024
Healthcare as a sector represents only about 12% of the S&P 500. If you want to overweight healthcare as a sector you need to add equities. Healthcare is usually a defensive sector because of...
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Industry Comparison: Evaluating Regeneron Pharmaceuticals Against Competitors In Biotechnology Industry
May 02, 2024
Via
Benzinga
Regeneron Earnings Miss; Biotech Giant's Stock Falls
May 02, 2024
The biotech giant's earnings and sales both missed Q1 estimates.
Via
Investor's Business Daily
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
May 13, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Sell In May? No Way!
May 11, 2024
Many investors and members of the financial media have been asking if it would be prudent to heed the old Wall Street adage to “sell in May and go away.
Via
Talk Markets
Will the Biotech Sector Shift From Lagger to Leader?
May 10, 2024
The biotech sector has experienced a significant rally after bouncing off uptrend support and is now consolidating near major SMAs.
Via
MarketBeat
Topics
ETFs
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
May 08, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends
April 30, 2024
Via
Benzinga
Regeneron Announces Investor Conference Presentations
May 06, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
May 04, 2024
Don’t miss out on these stocks that could rock your portfolio with massive growth following FDA approvals and breakthrough treatments.
Via
InvestorPlace
Exposures
Product Safety
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
May 03, 2024
The Nasdaq regained its 50-day line Friday. The other indexes hit resistance.
Via
Investor's Business Daily
Topics
Economy
Exposures
Interest Rates
Shhh! 3 Secret Pharma Stocks Flying Below Wall Street’s Radar
May 03, 2024
Discover three under-the-radar pharma stocks poised for significant growth in 2024. Explore their product pipelines and potential gains.
Via
InvestorPlace
Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation
May 02, 2024
Regeneron Pharmaceuticals Q1 2024 earnings: EPS down 5%, sales miss; Eylea US sales drop 16%, Dupixent offsets. Oncology treatment Libtayo sales surge 49%.
Via
Benzinga
Wall Street Inches Up After Powell's Inflation Remarks; Chipmakers Rebound; Gold, Crude Falter: What's Driving Markets Thursday?
May 02, 2024
U.S. stock markets surged during Thursday’s midday trading session in New York, with major averages all showing gains.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
REGN Stock Earnings: Regeneron Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
May 02, 2024
REGN stock results show that Regeneron Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years
May 02, 2024
Via
Benzinga
3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
May 02, 2024
It pays to develop novel medicines for life-threatening illnesses.
Via
The Motley Fool
Regeneron Reports First Quarter 2024 Financial and Operating Results
May 02, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
April 30, 2024
Via
Benzinga
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
April 29, 2024
Long-term data and subgroup analyses from pivotal EYLEA HD clinical program continue to demonstrate durable efficacy and consistent safety in patients with wet age-related macular degeneration and...
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
April 25, 2024
AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficacy and rapid skin clearance than Dupixent.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
39
40
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.